Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study

Biagio, Antonio Di; Rosso, Raffaella; Vitale, Francesco; Cardinale, Fabio; Sormani, Maria Pia; Secondo, G; Stefano, L. Di; Viscoli, Claudio

doi:10.5414/cnp75518

Cited by 17 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As additional findings, we documented that patients treated with TDF at 300 mg/daily showed a wide distribution of TDF plasma trough concentrations, and confirmed that renal function and body weight were the two major sources for the observed interindividual variability of TDF pharmacokinetics, as previously reported [21]–[23]. These observations underline the importance of close monitoring for renal and bone function in patients with low body weight treated with conventional TDF dose regimens [13], [14].…”

Section: Discussionsupporting

confidence: 85%

Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events

et al. 2013

View full text Add to dashboard Cite

Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight<50 kg had significantly higher plasma tenofovir concentrations than those weighting >50 Kg (160±93 vs.71±52 ng/mL, p<0.001). High tenofovir plasma trough concentrations and the age of the patients were independently associated with the development of drug-related kidney and bone toxicity. In this retrospective study we have shown that HIV-infected women with low body weight are at risk to be exposed to high tenofovir plasma trough concentrations, ultimately resulting in a significant hazard to develop long-term tenofovir complications.

show abstract

Section: Discussionsupporting

confidence: 85%

Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Some authors have reported female gender as a cause of higher concentrations of TDF [23]. However, a European population study did not find female gender as a predictor of renal damage [24]. Age was associated with renal toxicity in similarity with other studies [18,25].…”

Section: Resultssupporting

confidence: 56%

Incidence and Risk Factors of Renal Impairment in Hiv-1 Infected Patients Receiving Tenofovir Based Antiretroviral Therapy in a South Indian Hospital

Kumar

Parthasarathi

Sudheer

et al. 2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: To identify the incidence and risk factors of tenofovir (TDF) induced nephrotoxicity among People Living with HIV/AIDS (PLHA) receiving TDF-based anti-retroviral therapy (ART) in a South Indian Hospital.Methods: A retrospective cohort study was conducted among HIV-infected ART naïve patients taking TDF as part of either a first-line or second-line ART between July 2013 and June 2015 at Asha kirana Hospital Mysore, India.Results: A total of 380 patients have been initiated on TDF-based ART. Out of these, 335 patients were on tenofovir+lamivudine+efavirenz, 30 patients were on the tenofovir+lamivudine+nevirapine regimen and 25 patients were on tenofovir+lamivudine+atazanavir/ritonavir regimen. Renal impairment was documented for 35 patients with 9.21% incidence. 34% of renal impaired patients had a severe impairment with eGFR<30 ml/min. Elderly patients (>61 y) had higher chances of developing TDF toxicity compared to adult patients (P=0.0018). Other possible risk factors for TDF-induced renal impairment was CD4>200 (P=0.003). TDF was withdrawn and substituted with Nucleoside Reverse Transcriptase Inhibitor (NRTI) drug following the diagnosis of renal impairment.Conclusion: TDF-associated renal impairment was not uncommon in real-life practice and considered as a frequent complication during treatment with TDF. Risk factors for developing renal impairment include increasing age and CD4>200 cells.

show abstract

“…Some authors have reported female gender as a cause of higher concentrations of TDF [40]. However, a European population study did not find female gender as a predictor of renal damage [45].…”

Section: Discussionmentioning

confidence: 97%

Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients

et al. 2015

View full text Add to dashboard Cite

show abstract

Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study

Cited by 17 publications

References 0 publications

Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events

Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events

Incidence and Risk Factors of Renal Impairment in Hiv-1 Infected Patients Receiving Tenofovir Based Antiretroviral Therapy in a South Indian Hospital

Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients

Contact Info

Product

Resources

About